Allovir Inc Discussion on the Potential Clinical Impact of Posoleucel for the Treatment of BK Viremia in Kidney Transplant Patients - Corporate Call Transcript
Good morning, everyone, and welcome to AlloVir's virtual investor event to discuss the top line final results from our Phase II randomized double-blind placebo-controlled study of posoleucel in kidney transplant with BK viremia. I'm Sonia Choi, AlloVir's Senior Vice President of Corporate Affairs and Investor Relations and your host for today's call.
During today's call, AlloVir's CEO, Dr. Diana Brainard, will discuss the study findings and talk about next steps. Following her presentation, we'll open the Q&A section of our call. Dr. Brainard and Dr. Anil Chandraker; Director of renal transplant plant medicine at Brigham & Women's Hospital and principal investigator of the posoleucel BKV treatment study will be available to provide additional context for the need for new treatment options in this patient population and answer questions about the study results. Vikas Sinha, AlloVir's Chief Financial Officer, will also be available for questions. (Operator Instructions)
Before I turn the call over to Dr. Brainard, I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
